Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Clinical Trials

Protocol #

Protocol Name

Status

Cervical Treatment Protocols

G9918A Phase I Trial of Tailored Radiation Therapy with Concomitant Cetuximab (C225,NSC #714692) and Cisplatin (NSC #714692) in the Treatment of Patients with Cervical CancerOpen

Uterine/Endometrial Treatment Protocols

G209

Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or recurrent Endometrial Cancer

Open
G210A Molecular Staging Study of Endometrial CarcinomaOpen
G0087MA Phase II Evaluation of Trabectedin (Yondelis, R279741, IND#75,111) in the Treatment of Advanced, Persistent, or Recurrent Uterine LeiomyosarcomasOpen

Ovarian Protocols

KTN32313R
J07107

A Phase 3 Study of Safety and Efficacy of Karenitecin versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Epithelial Ovarian CancerOpen
IP Spore
J0741
Pilot Trial of Intraperinteal Paclitaxel and Carboplatin with IV Avastin Therapy in The Treatment of Women with Newly Diagnosed, Optimally Cytoreduced Carcinoma Of Mullerian OriginOpen
G9916A Phase I Trial of Intravenous Paclitaxel Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel inPatients with Previously Untreated Epithelial Ovarian Carcinoma, Fallopian Tube or Primary Peritoneal CarcinomaOpen
G9917A Dose-Escalating Phase I Study with an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC#214240) and Intravenous Paclitaxel (NSC# 673089) in Patients with Previously Untreated Epithelial Ovarian, Primary Peritoneal,or Fallopian Tube CarcinomaOpen
G218A Phase III Trial of Carboplatin and Paclitaxel plus placebo versus Carboplatin and Open Paclitaxel Plus Concurrent Bevacizumab (RhuMab VEGF, NSC #704865, IND#7921) followed by placebo, versus Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated suboptimal advanced stage Epithelial Ovarian and Peritoneal Primary CancerOpen
Agensys 2008001A Phase 1, Open-Label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics Submitted of AGS-8M4 Given as Monotherapy in Subjects with Advanced Ovarian CancerOpen

Acquisition Protocols

GOG 136Acquisition of Human Gynecologic Specimens and Serum to be used in Studying the Causes, Diagnosis, Prevention and Treatment of CancerOpen

Non-Treatment Protocols

J9883Acquisition of Gynecologic Tissues, Ascites and Serum SpecimenOpen
J-0073Patterns of Ovarian Cancer Surgery in MarylandOpen
04-02-05-10eTo Develop T-cell Based Immunotherapy for the Treatment of Ovarian CancerOpen
03-03-19-10dDatabase of Clinical Information for all Kelly Gynecologic Oncology Service Patients with a Cancer Diagnosis on a Secure, Encrypted WebsiteOpen
04-11-19-01Comparison of Preoperative VEGF and COX-2 Immunohistochemical Staining With Final Pathologic Diagnosis in Patients Initially Diagnosed with Atypical Endometrial HyperplasiaOpen
NA_00001222Oncotech Extreme Drug Resistance Assay; the Prognostic Significance of Molecular Regulations on Optimal Cytoreductibility and Chemotherapy Response Prediction in Women with Borderline Tumors of the Ovary and Ovarian CancerOpen
NA_000001205Mesenteric Lymph Node Involvement in Patients Undergoing Colorectal Resection for Epithelial Ovarian Cancer Open
NA_00001185Clinical Characteristics and Biochemical Markers that Define the Optimal Patients for Hormonal Management of Complex Atypical Hyperplasia and Endometrial CancerOpen
NA_00001195The Role of Secondary Cytoreductive Surgery for Recurrent Epithelial Ovarian Cancer Open
05-06-30-02Patterns of Surgical care for Uterine Cancer in MD during 1990-2000:  Physicians and Hospital Care VolumeOpen
04-07-02-09eIsolation of Cancer Stem Cells in Epithelial Ovarian Carcinoma (Matsui)Open
NA_00001982Surveillance Analysis for Recurrent Ovarian CancerOpen
NA_00002481Radical Surgical Procedures to Achieve Optimal Cytoreduction and the Impact on Disease free IntervalOpen
NA_00001945Clinico-Pathological features of Carcinosarcoma (Malignant Mixed Mesodermal Tumors) of the Uterus and OvaryOpen
NA_00002695Evaluation of Natural Killer T Lymphocytes in Immune Response Against Ovarian CancerOpen
NA_00002171Surgical Staging of Borderline Ovarian TumorsOpen
NA_00002959Clinical value, cost effectiveness and predictive factors of intra-operative findings in Patients with early endometrial cancer as compared to other modalitiesOpen
NA_00005472Immuno-Modulating Effects of AscitesOpen
NA_00003653 - J0787A Multicenter Trial on the Utility and Impact of Computed Tomography and Serum CA-125 in the Management of Newly Diagnosed Ovarian CancerOpen
NA_00017236Investigation of the Feasibility of Intravenous Gemcitabine and Cisplatin in the Treatment of Ovarian CancerOpen
NA_00001040The Use of Daily Goals Form to Improve Communication in the Gynecologic Oncology Unit.Open

 

 

 

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

U.S. 1-410-464-6713 (toll free)
International +1-410-614-6424

 

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer